3 ms·
>How do you see the risk of the most greedy company bidding the most to get privileged access to the data, and coming up with a cure that out-prices you or your
by drusepth 7y ago
>How do you see the risk of the most greedy company bidding the most to get privileged access to the data, and coming up with a cure that out-prices you or your family if you ever end up hit by the disease?
Is that preferable to an alternative where no company can bid on such data, and therefore a cure either never exists or is delayed N years (where N is probably significant)?
Consider also that all medicine often starts prohibitively expensive to offset R&D, and predictably lowers in cost over time.
- gowld 7y ago"Mylan now offers the authorized generic for Epipen for roughly $150 to $350 for a two-pack" (which expires after 1 year.)